Pipeline updates are highly awaited events in the
pharma/biotech sector as they play an important role in deciding
whether or not to invest in a particular company. Pipelines are
of prime importance as far as pharma/biotech companies are
concerned. These companies spend a significant amount in
advancing their pipelines.
) diabetes pipeline includes semaglutide, IDegLira, Tresiba and
Ryzodeg. All four candidates are for the treatment of type II
Novo Nordisk has a strong presence in the diabetes care market
with one of the broadest diabetes portfolios in the industry.
Novo Nordisk stated that it commands a 27% market share of the
total diabetes care market.
Recently, Novo Nordisk joined forces with Zosano Pharma, Inc.
to develop a new transdermal presentation of semaglutide, once
weekly GLP-1 analogue. Under this deal, semaglutide will be
administered once weekly using Zosano's microneedle patch system
for the treatment of type II diabetes.
Firstly, Zosano and Novo Nordisk will carry out preclinical
experiments to verify delivery of semaglutide using Zosano's
microneedle patch system.
Zosano granted Novo Nordisk an exclusive global license to
develop and commercialize semaglutide using Zosano's microneedle
patch system. Novo Nordisk will market all products under this
deal, subject to approval.
Potential payments to Zosano could total above $60 million for
the first product and $55 million for every additional product.
Zosano is also eligible to receive royalties on sales of products
and will receive development support, as well as reimbursement of
all development and manufacturing costs.
We expect the company's diabetes candidates to continue to
make progress and contribute to growth.
Novo Nordisk carries a Zacks Rank #4 (Sell). Some
better-ranked players in the pharma industry include
Salix Pharmaceuticals Ltd.
). All three stocks carry a Zacks Rank #1 (Strong Buy).
ACTELION LTD (ALIOF): Get Free Report
ENDOCYTE INC (ECYT): Free Stock Analysis
NOVO-NORDISK AS (NVO): Free Stock Analysis
SALIX PHARM-LTD (SLXP): Free Stock Analysis
To read this article on Zacks.com click here.